A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
CompletedNCT00000866
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-07-31Target: 36Updated: 2021-10-28